Analysts expect Helius Medical Technologies to report Q2 2026 revenue of $3.50 million and an EPS loss of -$0.02, with the current stock price of $1.75 trading well below the $3.50 average analyst price target.
The central focus for investors is the commercial ramp-up of the PoNS device following its recent FDA clearance for stroke rehabilitation in June 2026.
Securing adequate CMS reimbursement for the PoNS Controller remains the critical hurdle for broad market access and long-term financial sustainability.
Furthermore, the company's recent strategic pivot to operate as a digital asset treasury under the "Solana Company" brand has introduced significant new volatility tied to its cryptocurrency holdings alongside its medical technology business.